[PGK] Thimerosal in Vaccines: A 'Profitable' Medical Population-Maiming Agent?

[Guest guest]

To All,

Attached is an editorial that states

my views concerning the nature of

Thimerosal and the apparent KNOWING

choice of Thimerosal, and NOT some

other organic mercury compound, to be

the " special form of mercury " used as

a " preservative " in the formulations

of vaccines and serums that was

apparently DESIGNED and CHOSEN to

provide the broadest organic mercury

poisoning risk to developing children

and pregnant women who were given, and

are still being given, Thimerosal-

preserved vaccine doses WITHOUT the

REQUIRED TOXICOLOGICAL PROOFS of

SAFETY (see: 21 CFR Section 610.15(a))

SINCE 1973.

Hopefully, all who read this editorial

will do so with an open mind.

Both the " doc " and the " pdf " versions of this editorial are attached.

For those who do not get attachments,

the TEXT of this editorial is as follows:

_____________________________________________

ROUGH TEXT OF EDITORIAL

_____________________________________________

EDITORIAL - 23-06-2010

Thimerosal in Vaccines: A

'Profitable' Medical Maiming Agent?

Introduction to Thimerosal, a Highly

Toxic Organic Mercury Compound

Since the mid-1800s, we have been, and

are being, exposed to increasing

background levels of elemental,

inorganic, and naturally occurring

organic mercury.

However, the history of mercury-

containing poisons turned much more

deadly when people began to make

synthetic organic mercury compounds

specifically designed to be more

toxic [1] to life than the common

environmental inorganic mercury

compounds.

[1] On a relative scale where

metallic mercury has a

relative toxicity of " 1 " ,

inorganic mercury compounds

typically are " 10 times more

toxic as a group and organic

mercury compounds are " 100 to

1000 " times more toxic on a

weight basis than metallic

mercury.

It is against this background that a

chemist, M. S. Kharasch, synthesized

a variety of " alkyl mercuric sulfur "

compounds, including sodium ethyl

mercuric thiosalicylate [2], in the

1920s.

[2] Based on recent studies, this

compound is on a molar basis

at least 10 times more toxic to

developing neurons and astrocytes

than the methyl mercury compounds

found in fish.

In 1928, the US Patent Office granted

Kharasch a patent ( " Alkyl Mercuric

Sulphur Compound and Process for

Producing it. US Patent 1,672,615 " ), relating to this alkylmercury sulphur-

containing compound, which he had

synthesized in the laboratory, and

to the process for producing it.

He assigned this patent, along with

two follow-on patents: " Kharasch, M.

S. 1932. Stabilized Bactericide and

Process of Stabilizing it. US Patent

1,862,896 " and " Kharasch, M. S. 1935.

Stabilized Organo-Mercuri-Sulphur

Compounds. US Patent 2,012,820 " , to

the company for whom he worked, Eli

Lilly and Company (Lilly) [3].

[3] These patents clearly established

the instability of water-

containing solutions of sodium

ethyl mercuric thiosalicylate

such as those in vaccine

formulations.

The " safety " studies Lilly-affiliated

personnel conducted on this compound

were limited to some cursory animal

toxicity studies that killed many of

the test animals, and a specious test

on some patients dying from bacterial

meningitis in the days before modern

antibiotics.

In spite of the obviously highly toxic

nature of this mercury compound and

its instability in water-containing

solutions, Lilly chose to manufacture

and market this compound under the

trade name " Merthiolate " [4] in the

1930s.

[4] " Mer " from mercury and " thiolate "

from thiosalicylate " . The other

trade names for this compound

include: Merfamin, Merthiolate

sodium, Mertorgan, Merzonin,

Merzonin sodium, SET, Thimerosal,

Thimerosalate, and, principally

in Europe, Thiomersal and

Thiomersalate.

Lilly sold Merthiolate as a 0.1%

alcohol solution [5] (Tincture of

Merthiolate), which it promoted as a

" safe " and " effective " over-the-

counter (O-T-C) topical antiseptic.

[5] As studies conducted in the 1930s

and 1940s clearly established,

the only effective antiseptic

was the alcohol in the tincture

- Merthiolate/Thimerosal, at

even levels of 0.1%, was neither

an effective antiseptic nor

bactericidal.

Lilly marketed this O-T-C antiseptic

without any valid toxicological proof

of either Merthiolate's " safety " (or

its " effectiveness " as an antiseptic

beyond that of the alcohol in which it

was dissolved) from the early 1930s.

It also used this compound, also

trade-named Thimerosal, as a

preservative in the serum and vaccine

products Lilly sold until the mid-

1970s [6].

[6] When it exited the vaccines

business in the mid-1970s, Lilly

licensed the use of its

proprietary processes for the

manufacture of Thimerosal-

preserved vaccines to other

vaccine makers and, until 1994,

continued to make the Thimerosal

powder used in their manufacture.

In 1998, after decades of

procrastinating, the US Food and

and Drug Administration (FDA) banned

the use of Merthiolate/Thimerosal and

related mercury compounds as

ingredients in the manufacture of O-T-

C topical antiseptics and vaginal

contraceptives.

The FDA banned these uses of these

mercury compounds on the grounds that

they were neither safe to be

administered to humans nor effective

as a bactericidal agent in such

applications.

However, though the FDA recognized

Merthiolate's/Thimerosal's lack of

safety to humans at antiseptic levels

(nominally, 0.1 % by weight/volume)

and its failure to be an effective

antiseptic or spermicide, the FDA

continued to ignore the realities of

Thimerosal's toxicity when it is

used in the making of prescription

medicines, where it is used as a

preservative and its nominal levels

range up to 0.01% by weight/volume.

As of June 2010, the FDA continues

to permit the use of Thimerosal in

prescription drugs, including vaccines

and other biological drug products.

Thus, without the required

toxicological proofs of safety,

Thimerosal is still being used in

the manufacture of several FDA-

approved vaccines and other drugs.

From the early 1930s until the mid-

1970s, Lilly manufactured and

distributed Thimerosal-preserved

serums and vaccines under licenses

granted by the US National Institutes

of Health (NIH), which regulated

serums and vaccines.

In the late 1960s, because of the

NIH's mismanagement of vaccines, the

oversight for serums and vaccines was

transferred to the FDA.

Unfortunately, this transfer of

oversight to the FDA included the

transfer of key individuals from the

NIH to the FDA's then " Bureau of

Biologics " .

Among the transfers was the then head

of this FDA bureau, who continued to

allow the use of Thimerosal as a

preservative in biologics without the

required toxicological proofs of

safety.

Since 1973, all Thimerosal-containing

serums and vaccines for use in humans

have been regulated as biologics

(biological drug products) under Title

21 of the United States Code of

Federal Regulations (21 CFR) in

21 CFR §§ 600 - 680, in specific, and

under all of the applicable parts of

21 CFR, in general.

As of June 2010, the manufacturers who

use it have apparently not proven that

the use of Thimerosal as a

" preservative " in such biological

products is " safe " in the manner

required by law.

This is the case because 21 CFR §

610.15(a), the applicable current good

manufacturing practice (CGMP) drug

producer's minimum nondischargeable

" shall " compliance obligation,

specifically requires:

" Any preservative used shall be

sufficiently nontoxic so that

the amount present in the

recommended dose of the product

will not be toxic to the

recipient " [7].

[7] Note: Scientifically, the dose of

a compound is " nontoxic " when the

maximum level present is properly

proven to be below the compound's

NOAEL (no observed adverse-effect

level) when, in the intended

manner (injected in the case of

vaccines), the appropriate animal

surrogates for the most sensitive

group for which the use of the

compound is intended (for

vaccines, the most sensitive

groups are the fetuses of

pregnant women and developing

children) receives the maximum

amount permitted in a single dose

at a frequency that appropriately

matches the maximum in the most

sensitive group.

To be " sufficiently nontoxic " ,

as required here, the level of

the preservative dose must be

appropriately below the NOAEL by

more than one order of magnitude

(> a factor of 10).

For example, if the NOAEL for

injected Thimerosal in a vaccine

formulation is about 0.01

micrograms/kg of body weight/per

day, then a maximum level of

about 0.0001 micrograms/kg/day (a

factor of 100 lower) might be an

appropriate to ensure that the

dose delivered were " sufficiently

nontoxic " .

The need for a safety factor of

100, or more, arises because of

the highly toxic, bioaccumulative

nature of Thimerosal and its

metabolites.

In most current Thimerosal-

preserved vaccines, the nominal

level of Thimerosal is on the

order of nominally 100 micrograms

per milliliter.

Moreover, the developing fetus

typically weighs in the range

from less than 1 gram to no more

than 6 kg.

Thus, it is obvious that

Thimerosal is much too toxic for

0.5-mL injections into the

pregnant woman (delivering

nominally up to 50 micrograms

of Thimerosal to the fetus) to

be safe since the maximum

level could exceed 50,000

micrograms of Thimerosal per

kilogram of fetal weight during

the early weeks of pregnancy!

Today, Thimerosal, sodium ethyl-

mercurithiosalicylate, is a recognized

human teratogen, mutagen, carcinogen,

immune-system disruptor, and

reproductive toxin at levels

well below 1 part per million (ppm).

With the preceding background in mind,

let us consider the " criteria " for a

profitable medical population-maiming

agent and then assess how well

Thimerosal used as a preservative in

vaccines meets these criteria.

The " Criteria " for a Long-term

'Profitable' Medical Population-

Maiming Agent

1. Hidden sub-acutely toxic doses of

the poison must be given to each

cohort of developing children

before, or shortly after, birth

and periodically afterwards in

some medicine.

Ideally, for a mass poison that is

intended to " permanently " maim, but

not kill, many of those who are given

it, the poison needs to be given as

soon as possible to as many of the

target population as possible - in all

parts of the target country at about

the same time.

Thus, when the target is humans, the

first characteristic must be that,

before birth or as soon as possible

after birth, almost every child must

be covertly exposed to a suitably

" toxic " dose of the poison.

This non-lethal, sub-acutely toxic

dose must be sufficient to slowly

poison some small percentage of those

given it in a manner that, over time,

renders them chronically ill.

In addition, to maximize the

cumulative profit, almost every child

must be given multiple sub-acute doses

of this poison as he or she develops.

This tactic helps to ensure:

o The percentage chronically harmed

will increase over time, and

o The general population will be

slow to connect the harm done to

the concealed poison repeatedly

administered to the developing

children.

2. The doses of the poison must be

portrayed as contributing to the

" safety " of the product in which

they are placed and the public

must consider the products

containing the doses of poison to

be " vital " for developing children

to receive

To permit the poisoning to proceed for

a long time before anyone starts to

notice it, the population as a whole,

and especially those administering the

poisoning doses, must not notice the

poison or, if they do notice it,

perceive that the dose being given is

an insignificant dose.

In addition, the poison should be

presented as a contributor to the

" safety " of the medical product in

which it is delivered.

Finally, the poison should be

concealed in a medical product that

the public perceives, or is led to

believe, is necessary or vital for

most all children to receive.

3. Each small dose of the poison must

cause chronic disease in some who

are given more of it

The third key for an exquisite mass-

use poison is that only a single small

dose is required to cause long-term

toxic effects in some, with successive

doses causing increasing effects in an

increasing percentage of the

population.

4. The poison's effects must be time

delayed and/or slow to develop

The fourth attribute for a near-ideal

mass poison is that its observable

poisoning effects must be delayed

and/or slow to develop so that the

resulting poisoning is not closely

associated with the maiming doses'

delivery.

5. The poison must be a systemic

Poison

The fifth characteristic for an

" ideal " mass poison is that it must be

a systemic poison that affects all of

the biological systems of the targeted

population to varying degrees.

This ensures that the agent's harm is

harder to recognize because the

poison's effects are not be limited to

one specific organ (e.g., heart) or system (e.g., immune system).

6. When recognized, the poison must

be difficult to remove and/or to

reverse its ill effects

The sixth attribute for a mass poison

designed to provoke chronic disease

must be that, once the poisoning is

finally recognized, the poison's final

metabolic products must be

bioaccumulative persistent toxins that

are difficult to remove from the body

or hard to neutralize - making the

chronic effects difficult and/or

medically costly to reverse.

7. The poison and/or its metabolites

must be soluble in aqueous and

non-aqueous systems

The seventh design parameter for an

effective mass poison must be that the

poison and/or its immediate toxic

metabolites are soluble in both

aqueous (hydrophilic) and non-aqueous

(hydrophobic) regions of the body to

ensure that as many organs and systems

as possible are adversely affected in

as many manners as achievable in the

target population.

8. The poison must induce multi-

generational adverse genetic

and/or epigenetic effects in some

of those who are dosed with it

The eighth key characteristic is that

the poison must have some probability

that some of its adverse health

effects will be passed on to some of

the offspring that those who are

directly poisoned may subsequently

bear or father so that, even when the

poison's use is finally stopped, it

will continue to generate chronic

illness in some children for

generations to come.

9. The Establishment must claim that

the poison is " safe " and block

the requisite toxicity studies

that would prove it is not " safe "

The ninth key, for our ideal mass

poison, is that the medical

establishment, drug makers, health

officials, all the relevant government

agencies and the mainstream media must

not only claim that this poison is

" safe " at the level used but also

refuse to conduct, and/or otherwise

block, the appropriate toxicity

studies that would reveal its true

toxicity.

Thimerosal at Preservative Levels

in Vaccines:

An Ideal Poison for Medical Mass

Maiming?

From the history of its discovery,

isolation and characterization, it is

clear that Thimerosal is not stable

when dissolved in aqueous environ-

ments.

Then, why would any firm knowingly

choose Thimerosal for use as a

preservative in water-based (aqueous)

vaccine formulations when it is

unstable in aqueous solutions?

Moreover, if one were looking for a

preservative that was " safe " and

" effective " , why would a firm choose

to use Thimerosal, a compound that:

o Becomes more toxic over time

when dissolved in isotonic pH-

buffered physiological saline,

and

o Rapidly losses its effectiveness

as a " preservative " in serums

and vaccines, when exposed to

common protein components present

in such products?

Yet, Lilly used Thimerosal/Merthiolate

as a preservative (nominally, at .01%)

in its serum and vaccine products from

the 1930s until the mid-1970s when it

exited the vaccines business.

In addition, along with other firms,

Lilly marketed Thimerosal as an O-T-C

topical antiseptic (Merthiolate) until

the late-1990s, when, on the grounds

of a lack of safety and a lack of

effectiveness unequivocally

established in the 1970s, the FDA

finally banned its use as an

ingredient in such O-T-C antiseptics

and vaginal contraceptives.

Further, the Thimerosal-preserved

early childhood vaccines (like Lilly's

DT and DPT vaccines) appear to meet

the first two criteria for a

profitable population-maiming agent:

1. An early population-wide

deployment that maximizes the

profit potential, and

2. The concealment of an

" inconspicuous " amount (1 part

in 10,000) of the agent as a

" helpful " substance (a

" preservative " ) in " life saving "

vaccines given several times in

early childhood.

Thus, besides Tincture of Merthiolate,

touted as a " safe " and " effective "

topical antiseptic but not universally

used by pregnant women or on young

developing children, the first

Thimerosal-based mass-maiming agents

deployed appear to be the injected

Thimerosal-preserved DT and DTP

Vaccines [8], which Lilly made for

administration to babies several times

before their first birthday.

[8] After Lilly exited the vaccine

market, other vaccine makers,

principally what is now Sanofi

Pasteur and GlaxoKline as

well as other vendors have

marketed Thimerosal-preserved

vaccines including some that are

still being manufactured to this

very day and are approved for US

use.

From the 1980s until the early

2000s, in addition to Thimerosal-

preserved DT and DTP vaccines,

Thimerosal-preserved Td, TT, Hib,

Hep B, Meningococccal,

Inactivated-influenza and other

vaccines were approved for use in

various population segments

including, for the Hib and Hep B

vaccines, children.

With the phasing out of the

Thimerosal-preserved DTP, Hib and

Hep B vaccines as well as the

Thimerosal-preserved Rho(D)

products given to Rh-negative

women during pregnancy in the

early 2000s, in 2002, the CDC

moved to replace the lost

Thimerosal-maiming doses with the

mercury in inactivated-influenza

shots to be given to pregnant

women and children 6 months to 23

months of age.

By steadily increasing the

upper end of the age range for

the children until it was up to

18 years in 2009, recommending 2

shots the first time a child is

vaccinated for influenza, and, in

the 2009-2010 flu season, adding

recommendations that included one

Thimerosal-preserved inactivated-

influenza 2009-A-H1N1 vaccine for

pregnant women and two additional

doses of what could be a

Thimerosal-preserved 2009-A-H1N1

vaccine for children under 9

years of age and 1 dose for those

over nine years of age, the CDC

has effectively more than

replaced the mercury removed for

most of the pregnant women and

children because most doses of

the inactivated-influenza

vaccines (nearly 100% in the

2002-2003 flu season, and at

least 75% in the 2009-2010 flu

season) were Thimerosal-preserved

doses.

The CDC's recommendation to

give flu shots to pregnant women

is particularly egregious because

all flu vaccines are: a)

" Pregnancy Category C " drugs,

whose fetal and reproductive

safety and effects have never

been properly established and

drugs that have also not been

tested for mutagenicity and

carcinogenicity.

These Lilly vaccines were touted as

life saving drugs that " immunized "

(bulletproofed) children from getting

deadly diseases, diphtheria (D),

tetanus (T), and pertussis (P;

whooping cough), which were often

fatal.

Moreover, each dose of these

" preserved " vaccines directly

delivered nominally 50 micrograms of

Thimerosal (25 micrograms of organic

mercury) - a level that is more than

sufficient to cause a low-level of

harm in susceptible babies [9].

[9] Based on the only FDA-recognized

chronic rat study for injected

Thimerosal, the " nontoxic " level

for injected Thimerosal is

somewhere below 0.0042 microgram

of Thimerosal-derived mercury

per kilogram per day [see:

per kilogram per day [see:

http://mercury-freedrugs.org/docs/090812_fnldrft_TheTruthAboutTheToxicityOfT

himerosalr5b.pdf,

" The 'Truth' About The Toxicity

Of Thimerosal (12 August 2009; 6

pages) " ].

Based on several independent

retrospective statistical population

records studies, an exposure increase

of 200 micrograms of Thimerosal (100

micrograms of organic mercury) in

children vaccinated during their first

year of life has been proven to be a

statistically significant, or nearly

statistically significant, population

risk factor for a variety of serious

childhood medical conditions (e.g.,

autism, tics, and, most recently,

premature puberty).

In some reported monkey studies, a

single weight-proportional birth dose

of a Thimerosal-preserved hepatitis B

vaccine has been shown to cause

subtle, but serious, adverse effects

on their early development.

Thus, Thimerosal, at preservative

levels in vaccines, appears to meet

the third criterion.

Moreover, the principal persistent

adverse effects, like loss of words,

failure to thrive, tics, or premature

puberty, that have been linked to

Thimerosal exposure from the injection

of Thimerosal-preserved vaccines, are

delayed effects.

In most cases, the exposed infant in

America appears to progress normally

for some period after the initial or

one of the subsequent poisonings

(e.g., at 2, 4, and 6 months for the

Thimerosal-preserved DTP vaccines up

until 2004, or at before birth and 6

[and 7] months for the Thimerosal-

preserved flu shots that the CDC

started 'encouraging' healthcare

professionals to give pregnant women

and healthy babies in 2002) [10].

[10] Building on the DTP program,

the Thimerosal exposures were

increased to at birth, 2 and 4

to 6 months when the early

hepatitis B program was

introduced in the 1990s, in

addition to 3 more doses (at 2,

4, and 6 months) from the Hib

vaccines introduced in the late

1980s.

Further, as the level of

Thimerosal was being reduced in

the early childhood vaccines,

the CDC started making

recommendations that pregnant

women and healthy children at 6

to 23 months of age receive the

Thimerosal-preserved

inactivated-influenza vaccines

in 2002.

Currently, the CDC recommends

inactivated-influenza

vaccination for pregnant women

and children at 6 and 7 months

and annually thereafter, where

the majority (not less than 75%)

of the available doses are

Thimerosal-preserved.

In addition, in 2009 the CDC

recommended an additional 2009-

A-H1N1 inactivated-influenza

vaccine shot for pregnant women;

two of these flu shots for

children up to age 9; and one of

these flu shots for those 9 and

older - where most all of the

available doses of the 2009-A-

H1N1 flu shots were again

Thimerosal-preserved

inactivated-vaccine doses.

Then, the susceptible exposed infant

begins to " regress " or " change " as the

symptoms of the maiming become evident

months (usually, at or after 1 year of

age) or, in the case of premature

puberty (and probably childhood MS),

several years later.

Thus, Thimerosal clearly satisfies the

fourth, " effects delayed and/or slow

to develop " , criterion for an

effective population-maiming agent.

Thimerosal clearly satisfies the fifth

criterion because it is a proven

systemic human poison at low levels

(part-per million and lower).

For example, Thimerosal is a known

human carcinogen, mutagen, teratogen,

immune-system disruptor and

reproductive toxin (by California Prop

65 criteria) at levels below 1 part-

per-million (ppm) of Thimerosal in the

body.

Further, Thimerosal's end-product

metabolites are tissue-bound inorganic

mercury species that have human half-

lives on the order of one to two

decades, depending on the tissue.

Thus, it is clear that Thimerosal is a

bioaccumulative persistent toxin.

Moreover, as studies in monkeys have

established, the tissue-bound

" inorganic mercury " species form

faster when an ethyl mercury compound

was administered than when a similar

methyl mercury compound was

administered.

In addition, even when aggressive

" mercury chelating " agents, like DMSA

and DMPS, are used, the level of

mercury " bound " in the tissues can

only be slowly reduced.

Typically, chelation takes years to

significantly reduce the poisoned

individuals' body-burden of tissue-

associated, " inorganic " mercury to

the point that those reversible [11]

symptoms induced by the mercury-

poisoning events are minimized or,

in some instances, are apparently

eliminated.

[11] Unfortunately, unless tested

for mercury toxicity and treated

before the adverse effects

produce persistent symptoms,

some of the developmental harm

done seems, at present, to be

non-reversible in many

instances.

Thus, Thimerosal has the character-

istics required for the sixth key

attribute for a maiming poison because

any exposure to it can slowly provoke

a wide range of chronic adverse

clinical conditions and its mercury-

containing end-point metabolites

(tissue-bound " inorganic mercury " ) are

difficult to remove from the tissues

in which they reside.

Further, when a Thimerosal-containing

solution enters the human body, the

Thimerosal present reacts with the

body's aqueous fluids to form the

following organic compounds:

? Ethyl mercury chloride (EtHgCl),

which is highly lipophilic

(hydrophobic);

? Ethyl mercury hydroxide (EtHgOH),

which is highly hydrophilic; and

? Sodium thiosalicylate, which is

further metabolized in the body.

Since both of the initial ethyl-

mercury-containing metabolites of

Thimerosal are small neutral species,

they:

? Are easily transported within the

human body;

? Apparently cross or circumvent the

blood-brain barrier and cross the

placenta and enter the fetus; and

? Once inside a given tissue, are

rapidly converted into tissue-

associated " inorganic mercury "

that tends to bioaccumulate in

that tissue.

Given the preceding realities, it is

clear that Thimerosal and its mercury-

containing metabolites directly and

indirectly poison almost all human

biological processes to some degree

wherever a mercury species can

interfere with the body's fundamental

systems.

Thus, Thimerosal's rapid breakdown in

the human body into small neutral

mercury-poisoning metabolites (that

are both hydrophilic and hydrophobic

and which migrate into the tissues and

are converted into tissue-resident

" inorganic mercury " ) satisfies the

seventh criterion for an exquisite

mass-maiming poison.

Further, based on multi-generational

reproduction experiments done in the

former Union of Soviet Socialist

Republics (USSR) [12], sub-acute

Thimerosal exposure is clearly capable

of inducing epigenetic and/or genetic

changes in the offspring who are

exposed to Thimerosal in utero.

[12] Goncharuk GA. Experimental

investigation of the effect

of organomercury pesticides

on generative functions and

on progeny. Hyg Sanit. 1971;

36: 40-43.

The changes induced in utero were

shown to be expressed in the non-

Thimerosal-exposed second-generation

offspring of the first-generation of

indirectly exposed offspring.

Thus, Thimerosal, used as a preservative

in vaccines, appears to be a multi-

generational poison.

Moreover, these experimental findings

help to explain why the then USSR,

already experiencing a population

decline, was the first European

nation to ban the use of Thimerosal

in vaccines (in the early 1980s) -

more than 2 decades before the US

finally began slowly reducing the

level of Thimerosal in the previously

Thimerosal-preserved early childhood

vaccines.

While, obviously driven by other

imperatives, the FDA continued to

approve additional Thimerosal-

preserved vaccines (e.g., the vaccines

for hepatitis B and Haemopholis

influenza type and the Centers for

Disease Control and Prevention (CDC)

continued to add these additional FDA-

approved Thimerosal-preserved vaccines

to the recommendations for the

national childhood vaccination

program.

Thus, Thimerosal apparently meets the

eighth key attribute for a near-ideal

population-maiming toxin - its maiming

effects can be transferred to the

offspring of mothers who were

themselves exposed during pregnancy

as long as these in-utero-exposed

'potential mothers' are not so damaged

that they are " miscarried " or they

cannot bear children.

Finally, given:

? The official positions taken by

the medical establishment, the

vaccine makers, the health

officials, academia, all relevant

governmental agencies and the

mainstream media that the use of

Thimerosal as a preservative in

vaccines is " safe " and

? The refusal of all to conduct (or

report to the public) all of the

applicable toxicity studies

required to prove that this use of

Thimerosal is " safe " ,

Thimerosal clearly satisfies the ninth

key factor for a near-ideal popula-

tion-maiming poison that is touted as

" beneficial " component (a preserva-

tive) and added to " life saving "

vaccines that all American children

are recommended to be repeatedly

given.

Thimerosal at Preservative Levels

in Vaccines:

A Near-ideal Medical Agent for

'Profitable' Mass Maiming

Thus, Thimerosal's use as a " presser-

vative " in medical vaccines seems to

meet all nine (9) of the criteria for

a 'profitable' medical mass-maiming

poison.

Further, it seems clear that Lilly and

the current vaccine manufacturers, which,

without complying with 21 CFR § 610.15(a),

continued to use Thimerosal as a

preservative in vaccines and/or to

apparently profit from its on-going

use, have been knowingly engaged in

the apparent medical poisoning of

American children for decades in order

to, at some point, profit over several

decades from the Thimerosal-induced

increase in the level of children in

the USA who have life-long chronic

health conditions (e.g., for 'autism',

from less than 1 in 1000 children born

in 1955 to more than 1 in 100 born in

2005; and, for asthma, from less than

1 in 1000 children in the 1950s to

greater than 1 in 10 born in the 21st

century).

Finally, these actions have apparently

been, and are still being, undertaken

with the tacit consent and/or assis

tance of all the Thimerosal-use-sup-

porting facets of the Establishment.

Disclaimer

**************************************

* The information provided in this *

*editorial is just that-information. *

* It is not medical advice and it *

*does not require any specific action*

*or actions. *

* While the statements made are *

*thought to be accurate, no *

*representations are made as to their*

*accuracy other than that they are my*

*best understanding of the facts on *

*the date that this editorial was *

*first published on the Internet. *

* All should verify the accuracy of *

*the information provided for them- *

*selves before acting on it or *

*reacting to it. *

**************************************

Concluding Remarks

Should any reader find significant

factual errors in this editorial, then

please send the author (at drking@...)

your proposed changes along with e-mail

attachments that contain copies of the

published documents that provide the

proofs needed to substantiate your

claims.

Then, as has been the case in the

past, after verifying the validity of

your concerns, the confirmed factual

errors will be corrected and an

appropriately " revised editorial "

posted.

If you find spelling, grammar or

textual errors, please also send them

in so that this document can be

appropriately revised and posted as an

" updated editorial " .

END OF ROUGH TEXT

Respectfully,

G. King, PhD

http://www.dr-king.com